Hydroxyzine: Discovery, Development, Safety and Pharmacovigilance
Hydroxyzine is an instructive example of an established medicine whose benefit–risk balance changed after decades of use. Its first-generation H1 antihistamine activity helps relieve pruritus; central nervous system penetration produces sedation and contributes to its use in anxiety. Later cardiac safety review demonstrated a small but important risk of QT prolongation and torsade de pointes (TdP), particularly with susceptible patients and interacting medicines. [1,2]
- Hydroxyzine: Discovery, Development, Safety and Pharmacovigilance
Discovery and lifecycle
Hydroxyzine entered clinical use in 1955; the sponsor's historical pharmacovigilance analysis uses 14 December 1955 as its international birth date. The available evidence establishes the market-era chronology but does not establish an individual inventor or the exact original synthetic experiment. The long-standing UCB product programme subsequently contributed to a published safety re-evaluation. Different salts, brands and formulations have separate national authorisations; one label cannot be assumed to represent them all. [2]
The current French public medicines database identifies a commercial declaration for the ATARAX 25-mg tablet presentation dated 19 January 1956, and an authorisation date of 16 August 1988. These are presentation-specific administrative milestones, not evidence that the molecule was invented or first authorised in either year. The 1955 international birth date and 1956 French marketing declaration provide independently distinguishable markers of the early commercial lifecycle. The originating synthesis, original individual inventors, and detailed first-in-human study chronology remain inadequately documented by the primary sources reviewed; no inventor or pivotal trial is assigned without reliable evidence. [2,7]
Hydroxyzine's early clinical introduction preceded modern hERG-channel screening and formal QT assessment. The subsequent identification of cardiac repolarisation mechanisms and ICH E14/S7B evaluation standards changed how regulators assess long-established noncardiac drugs. The 2015 EMA/CMDh review was a benefit–risk reassessment rather than a new-product approval. [1,2]
Pharmacology and clinical evidence
Hydroxyzine is a piperazine-derived first-generation H1 receptor antagonist. H1 blockade suppresses histamine-mediated wheal, flare and itching. Brain penetration explains sedation, while antimuscarinic effects contribute to dry mouth and impaired alertness. The parent drug undergoes hepatic metabolism, including formation of cetirizine, a separate active antihistamine with its own product information. Renal and hepatic impairment, age and co-medications can alter the clinical context. [3,4]
The 2022 Cochrane review of hydroxyzine for generalised anxiety disorder included five trials and 884 participants. Although some evidence favoured hydroxyzine over placebo, high risk of bias and limited evidence prevented recommending it as a reliable first-line GAD treatment. This finding concerns comparative evidence quality, not an assertion that hydroxyzine has no anxiolytic effect. Its pruritus indications remain separately relevant. [5]
From early use to modern benefit–risk evidence
The discovery history of an older medicine is not equivalent to the modern evidence package expected for a newly authorised active substance. Hydroxyzine was adopted during an era when symptomatic relief and observed tolerability often drove use, while systematic long-term cardiac electrophysiology testing was not yet routine. The subsequent history is best divided into early clinical availability, expansion across symptomatic indications, comparative efficacy assessment, and retrospective safety re-evaluation. The historical record supports the chronology of marketed use but not a reconstructed phase I–III programme with named pivotal studies. [1,2,5]
The therapeutic question also depends on the indication. For pruritus, central sedation can coexist with peripheral H1 antagonism; symptomatic improvement should not be mistaken for treatment of the underlying inflammatory or allergic disease. For anxiety, an apparent short-term benefit must be considered against sedation, impaired function, antimuscarinic effects and the availability of treatments with stronger long-term evidence. The Cochrane synthesis provides a useful example: a positive comparison with placebo in selected trials does not remove uncertainty from study quality, duration, patient selection or comparative effectiveness. [4,5]
Pharmacokinetics, accumulation and interactions
Hydroxyzine's clinical effects cannot be predicted from a single receptor-binding statement. The UK SmPC reports oral absorption, extensive distribution and metabolism to cetirizine, with a longer elimination half-life in elderly volunteers than in younger adults. It also describes increased exposure to the cetirizine metabolite in renal impairment. These observations support caution when evaluating delayed or persistent sedation, but they do not justify assigning a patient's symptoms to accumulation without dose history, renal/hepatic context and competing explanations. [4]
Two interaction mechanisms should be assessed separately. Pharmacodynamic interactions include additive CNS depression with alcohol, opioids, benzodiazepines and other sedatives, and additive arrhythmia risk with QT-prolonging drugs or hypokalaemia-inducing treatment. Pharmacokinetic interactions may involve medicines affecting hydroxyzine metabolism through alcohol dehydrogenase or CYP3A4/5, as described in the UK product information. A suspected interaction case should document when each medicine was started or stopped, actual dose, laboratory findings and observed effects rather than merely identifying a theoretical interaction pair. [4,7]
The cardiac safety turning point
The 2017 sponsor-supported analysis reviewed reports from 1955 through August 2016 and identified 59 reports of QT prolongation or TdP potentially associated with hydroxyzine. Except for intentional overdose, the cases had other recognised risk factors. Experimental testing demonstrated concentration-dependent inhibition of hERG potassium channels, supporting biological plausibility. Spontaneous-report counts and sponsor exposure estimates do not yield a reliable population incidence. [2]
In 2015, the EMA PRAC and CMDh recommended restricting use in patients with relevant QT risk factors, limiting exposure to the lowest effective dose and shortest duration, and discouraging use in older people. The European maximum daily doses were 100 mg in adults, 50 mg in elderly patients if unavoidable, and 2 mg/kg in children weighing up to 40 kg where authorised. Known prolonged QT, major electrolyte abnormalities, significant bradycardia, relevant cardiovascular disease and concomitant torsadogenic medicines are key contraindication/risk-factor categories. These European measures are not automatically identical to wording in a US label. [1,6]
Safety profile beyond arrhythmia
Sedation and anticholinergic effects
Drowsiness is prominent in product information. The practical concern is impaired driving, falls and injury, especially when alcohol, opioids or other CNS depressants are used. Dry mouth, psychomotor impairment and confusion require evaluation of timing, dose, organ function and competing causes. Elderly patients may be more susceptible to both anticholinergic effects and delayed elimination. [3,4]
Neurological and skin reactions
The selected US tablet label reports involuntary movements including rare tremor and convulsions, usually with higher doses. It also lists acute generalised exanthematous pustulosis and fixed drug eruptions in postmarketing experience. A new rash during treatment for pruritus is not automatically drug-induced: morphology, chronology, other medications and original skin disease matter. Severe eruptions require prompt clinical assessment. [3]
Overdose
Hydroxyzine overdose can cause profound sedation, neurological manifestations and QT prolongation. Co-ingestion and documented rhythm findings are central to case interpretation. Historical package-insert overdose instructions should not be used in place of contemporary emergency and poison-centre protocols. [3]
Product-specific listedness: US, France and UK
Documents, jurisdiction and scope
United States: Graviti Pharmaceuticals/Rising Pharma hydroxyzine hydrochloride film-coated oral tablets, DailyMed set 519e54e0-a613-e7b3-e063-6294a90a4452, version 1, prescribing text revised June 2024; checked 12 November 2026. This is a particular US oral-tablet label, not a universal hydroxyzine label. Its Adverse Reactions text names drowsiness, dry mouth, tremor, convulsions, QT prolongation, torsade de pointes and postmarketing severe skin reactions, but does not assign them European-style frequency categories. [3]
European Union (France): ANSM ATARAX 25 mg, comprimé pelliculé sécable, hydroxyzine dihydrochloride 25-mg scored film-coated oral tablet; French RCP updated 16 February 2026, checked 12 November 2026. The public database's general update of 3 November 2026 is not the individual RCP revision date. French indications include minor manifestations of adult anxiety, pre-anaesthetic medication, pruritus and a restricted second-line childhood sleep-onset indication after behavioural measures fail. This is a nationally authorised EU product, not a centrally authorised EMA medicine. [7]
United Kingdom: Morningside Healthcare hydroxyzine hydrochloride 25-mg film-coated tablets, PL 20117/0318; SmPC revised 27 August 2025, emc page updated 6 January 2026; checked 12 November 2026. UK authorised indications are adult anxiety and pruritus in specified skin conditions; the UK is not an EU member state. [4]
Direct adverse-reaction comparison
| Safety concept | US tablet, Adverse Reactions | French ATARAX, RCP §4.8 | UK Morningside, SmPC §4.8 |
|---|---|---|---|
| Somnolence/drowsiness | Listed without European frequency category | Placebo-controlled events 13.74% hydroxyzine (N=735), 2.70% placebo (N=630), irrespective of causality | Drowsiness/somnolence included in nervous-system row, frequency not known |
| Headache, fatigue, dry mouth | Dry mouth listed; do not infer trial frequencies for other terms from this US label | Trial events respectively 1.64%, 1.36%, 1.22% with hydroxyzine, versus 1.90%, 0.63%, 0.63% with placebo | Headache, fatigue and dry mouth appear in relevant rows, not known |
| QT prolongation and TdP | Listed, with cardiac warning | Ventricular arrhythmias (e.g. TdP) and QT prolongation, frequency not known; §4.3 contraindications and §4.4 warnings | Cardiac row lists both, frequency not known; §4.3–4.5 address cardiac risks |
| Convulsions/seizures | Reported, especially with higher doses | Convulsions described as rare in postmarketing narrative | Convulsions/seizure in nervous-system row, not known |
| AGEP, fixed drug eruption and serious blistering reactions | Postmarketing cutaneous reactions included | Very rare skin reactions include fixed drug eruption, AGEP and blistering syndromes including SJS/TEN | Skin row includes these terms; row classified very rare |
The French percentages are events irrespective of investigator attribution in specified placebo-controlled trials; they are not attributable risk, incidence in all users or estimates of contemporary real-world frequency. French postmarketing terms are presented narratively, with only some terms assigned explicit categories. The UK table uses not known for most system-organ-class rows but very rare for its skin row. It would be inaccurate to assign the French trial percentages or the UK frequency to the US product. [3,4,7]
The French RCP contraindicates use in known QT prolongation or specified risk-factor situations, including relevant electrolyte abnormalities and concomitant torsadogenic medicines; it also specifies end-stage renal impairment (GFR below 15 mL/min) as a contraindication. The UK SmPC has its own contraindication and dosing text, including a 100-mg/day adult maximum and avoidance in elderly patients where possible. These are product- and jurisdiction-specific statements, not universal rules for all hydroxyzine presentations. [4,7]
The comparison confirms listedness only for the named terms in the identified public labels and sections. An omitted term is not thereby unlisted. Public-label listedness does not establish company-core listedness, case-specific expectedness against effective reference safety information, causality, seriousness or reportability. Record the exact product and effective label version before any real ICSR determination.
Practical pharmacovigilance
A suspected hydroxyzine-associated arrhythmia requires the exact product, dose, formulation, onset, baseline and event ECGs, QTc correction method, electrolytes, renal/hepatic status, co-medications and rhythm documentation. Syncope alone does not establish TdP. Confirmed TdP, QT prolongation and syncope may be separate reportable clinical concepts when supported by the source. [1,2]
| Event | Priority follow-up | Key alternative or contributor |
|---|---|---|
| QT prolongation | Serial ECG/QTc, dose, potassium/magnesium, dechallenge | Congenital QT, bradycardia, interacting drugs |
| TdP | Rhythm strip, treatment, resuscitation, outcome | Structural heart disease, electrolytes, co-medication |
| Sedation or fall | Alertness, injury, timing, CNS depressants | Frailty, neurological illness, alcohol |
| Severe rash | Morphology, photos, fever, biopsy, other drugs | Underlying pruritic disease, infection |
| Seizure | Witness account, dose, co-ingestants, metabolic tests | Epilepsy, intoxication, withdrawal |
An illustrative older patient taking a QT-prolonging antidepressant and a potassium-lowering diuretic develops syncope after starting hydroxyzine. The assessment must separate the observed rhythm, possible pharmacodynamic interaction, electrolyte contribution and any pre-existing disease. Neither a positive temporal association nor a regulatory warning establishes the individual causal contribution of each medicine.
Signal evaluation and governance
For an increase in arrhythmia reports, review diagnostic confirmation, duplicates, reporting stimulation, co-medication patterns and exposure changes before interpreting disproportionality. The 2017 sponsor analysis combined targeted safety-database retrieval with mechanistic ion-channel experiments; its 59 historical reports cannot stand in for a current incidence estimate. [2]
An inspection-ready record retains original source facts, follow-up attempts, medical review, effective reference label, seriousness, causality, expectedness basis, submission decisions and signal-governance outcomes. Medication reconciliation, attention to European restrictions and monitoring of preventable co-prescription risks are practical controls; their exact mandatory status depends on the applicable jurisdiction and product conditions.
Case validity, medical judgement and traceability
A safety case may be valid without an ECG, but its diagnostic certainty must not be overstated. A reporter describing “fainted after a tablet” has supplied a clinically important event; it has not necessarily supplied confirmed ventricular arrhythmia. Capture the reporter's exact words, assess the minimum validity criteria under the applicable reporting framework, request targeted follow-up and code the medically supported event. If an ECG later establishes TdP, retain the original account and the chronology of diagnostic clarification. A corrected case should remain traceable to the source and follow-up records rather than silently replacing the initial report.
When multiple products are suspected, the role of each must be evaluated with the timeline. For example, hypokalaemia may reflect a diuretic, gastrointestinal loss or other illness; a QT-prolonging antidepressant may contribute pharmacodynamically; hydroxyzine exposure may be temporally relevant without being the sole cause. Record objective potassium and magnesium results, ECG timing, dose and dechallenge alongside plausible competing factors. A negative or missing rechallenge is not evidence against a serious arrhythmic event, and rechallenge should not be solicited merely to strengthen causality.
Risk minimisation across jurisdictions
The 2015 European review illustrates the distinction between a regulatory risk-minimisation decision and a local operational control. European product information was changed to limit exposure and restrict treatment in patients at higher risk of arrhythmia. A marketing-authorisation holder's practical implementation may involve updating product information, reviewing educational or prescribing communications where required, checking relevant co-prescription patterns, and evaluating whether controls reduce avoidable exposure. The applicable legal obligations must be established from each authorisation and national implementation, not inferred from this article. [1,6,7]
An effectiveness assessment can ask whether high-risk patients are still exposed, whether dose and treatment duration comply with current local product information, and whether severe cardiac symptoms are promptly recognised. Each measure needs a defined population, data source, time window and limitations. Reporting volume alone is a poor effectiveness measure because safety communications may increase reporting even when exposure to risky combinations declines. Conversely, fewer spontaneous reports cannot prove that the risk has disappeared.
Figure decision
The principal scientific relationships are H1 antagonism and sedation, concentration-dependent hERG blockade, and the interaction of patient susceptibility with concomitant medicines and electrolytes. A single arrow diagram could misleadingly imply that every exposed patient progresses from hERG inhibition to TdP. The product-specific comparison and case-follow-up tables preserve the distinction between mechanism, observed events and clinical modifiers more accurately than a deterministic flowchart. No additional figure is required for this article.
Key takeaways
Hydroxyzine combines useful antihistamine effects with central sedation and clinically important cardiac susceptibility. Its modern safety story demonstrates why decades of experience do not eliminate the need for ongoing pharmacovigilance. The decisive assessment is product-specific, jurisdiction-specific and grounded in both clinical evidence and competing risk factors.
References
- EMA. New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines. 2015. https://www.ema.europa.eu/en/news/new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines
- Schlit AF, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine. Pharmacol Res Perspect. 2017;5:e00309. https://doi.org/10.1002/prp2.309
- DailyMed. Hydroxyzine hydrochloride film-coated tablets, Graviti/Rising Pharma, version 1; text revised June 2024. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=519e54e0-a613-e7b3-e063-6294a90a4452&version=1
- Morningside Healthcare. Hydroxyzine hydrochloride 25 mg film-coated tablets, UK SmPC, revised August 2025. https://www.medicines.org.uk/emc/product/101785/smpc
- Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2022;3:CD006815. https://www.cochrane.org/evidence/CD006815_hydroxyzine-generalised-anxiety-disorder
- EMA. Hydroxyzine Article 31 referral, Annex III SmPC amendments. 2015. https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-iii_en.pdf
- ANSM. ATARAX 25 mg, comprimé pelliculé sécable. Résumé des caractéristiques du produit; RCP updated 16 February 2026, sections 4.1–4.9. Accessed 12 November 2026. https://base-donnees-publique.medicaments.gouv.fr/medicament/61519586/extrait
Regulatory Note
Educational pharmacovigilance reference only. Confirm the exact current local product information and applicable reference safety information before a clinical or regulatory decision. Historical US dosing and 2015 European restrictions must not be conflated.